Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development

Chemical Research in Toxicology

Volumn 22, Issue 2, 2009, Pages 280-293

  Leclercq, Laurent ^a   Cuyckens, Filip ^a   Mannens, Geert S J ^a   De Vries, Ronald ^a   Timmerman, Philip ^a   Evans, David C ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE;

ABSORPTION; COMPUTER PROGRAM; HUMAN; LIQUID CHROMATOGRAPHY; METABOLISM; NONHUMAN; RADIATION DETECTION; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SAMPLE; SPECIES;

ANIMALS; DECISION TREES; DRUG EVALUATION; GUIDELINES AS TOPIC; HUMANS; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS;

ANIMALIA;

EID: 62249142787     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx800432c     Document Type: Review

References (48)

1. Baillie, T. A., Cayen, M. N., Fouda, H., Gerson, R. J., Green, J. D., Grossman, S. J., Klunk, L. J., LeBlanc, B., Perkins, D. G., and Shipley, L. A. (2002) Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196.
2. Baillie, T. A. (2008) Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol. 21, 129-137.
3. Smith, D. A., and Obach, R. S. (2005) Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33, 1409-1417.
4. Hastings, K. L., El Hage, J., Jacobs, A., Leighton, J., Morse, D., and Osterberg, R. E. (2003) Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 190, 91-92.
5. Smith, D. A., and Obach, R. S. (2006) Metabolites and safety: What are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579.
6. Prueksaritanont, T., Lin, J. H., and Baillie, T. A. (2006) Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217, 143-152.
7. Roffey, S. J., Obach, R. S., Gedge, J. I., and Smith, D. A. (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab. Rev. 39, 17-43.
8. Ma, S., Chowdhury, S. K., and Alton, K. B. (2006) Application of mass spectrometry for metabolite identification. Curr. Drug Metab. 7, 503-523.
9. Mortishire-Smith, R. J., O'Connor, D., Castro-Perez, J. M., and Kirby, J. (2005) Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. Rapid Commun. Mass Spectrom. 19, 2659-2670.
10. Ruan, Q., Peterman, S., Szewc, M. A., Ma, L., Cui, D., Humphreys, W. G., and Zhu, M. (2008) An integrated method for metabolite detection and identification using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection. J. Mass Spectrom. 43, 251-261.
11. Tiller, P. R., Yu, S., Castro-Perez, J., Fillgrove, K. L., and Baillie, T. A. (2008) Highthroughput, accurate mass liquid chromatography/ tandem mass spectrometry on a quadrupole time-offlight system as a 'first-line' approach for metabolite identification studies. Rapid Commun. Mass Spectrom. 22, 1053-1061.
12. Cuyckens, F., Hurkmans, R., Castro-Perez, J. M., Leclercq, L., and Mortishire-Smith, R. J. (2008) Extracting metabolite ions out of a matrix background by combined mass defect, neutral loss and isotope filtration. Rapid Commun. Mass Spectrom. 23, 327-332.
13. Mortishire-Smith, R. J., Castro-Perez, J., Yu, K., Shockcor, J. P., Goshawk, J., Harsthorn, M., and Hill, A. W. (2008) Generic dealkylation: a tool for increasing the hit-rate of metabolite rationalization, and automatic customization of mass defect filters. Rapid Commun. Mass Spectrom., submitted for publication.
14. Liu, D. Q., and Hop, C. E. (2005) Strategies for characterization of drug metabolites using liquid chromatography-tandem mass spectrometry in conjunction with chemical derivatization and online H/D exchange approaches. J. Pharm. Biomed. Anal. 37, 1-18.
15. Benton, H. P., Wong, D. M., Trauger, S. A., and Siuzdak, G. (2008) XCMS2: processing tandem mass spectrometry data for metabolite identification and structural characterization. Anal. Chem. 80, 6382-6389.
16. Hill, D. W., Kertesz, T. M., Fontaine, D., Friedman, R., and Grant, D. F. (2008) Mass spectral metabonomics beyond elemental formula: chemical database querying by matching experimental with computational fragmentation spectra. Anal. Chem. 80, 5574-5582.
17. Stranz, D. D., Miao, S., Campbell, S., Maydwell, G., and Ekins, S. (2008) Combined computational metabolite prediction and automated structure-based analysis of mass spectrometric data. Toxicol. Mech. Methods 18, 243-250.
18. Hill, A. W., and Mortishire-Smith, R. J. (2005) Automated assignment of high-resolution collisionally activated dissociation mass spectra using a systematic bond disconnection approach. Rapid Commun. Mass Spectrom. 19, 3111-3118.
19. Leclercq, L., Mortishire-Smith, R. J., Huisman, M., Cuyckens, F., Hartshorn, M. J., and Hill, A. (2009) IsoScore: automated localization of biotransformations by mass spectrometry using product ion scoring of virtual regioisomers. Rapid Commun. Mass Spectrom. 23, 39-50.
20. Dear, G. J., Patel, N., Kelly, P. J., Webber, L., and Yung, M. (2006) TopCount coupled to ultra-performance liquid chromatography for the profiling of radiolabeled drug metabolites in complex biological samples. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 844, 96-103.
21. Brain, G. J., Waldmeier, F., Boernsen, K. O., Pfaar, U., Gross, G., and Zollinger, M. (2006) A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: validation and applications. J. Chromatogr., A 1133, 184-194.
22. Nassar, A. E. F., Bjorge, S. M., and Lee, D. Y. (2003) On-line liquid chromatography-accurate radioisotope counting coupled with a radio-activity detector and mass spectrometer for metabolite identification in drug discovery and development. Anal. Chem. 75, 785-790.
23. Cuyckens, F., Koppen, V., Kembuegler, R., and Leclercq, L. (2008) Improved liquid chromatography-online radioactivity detection for metabolite profiling. J. Chromatogr., A 1029, 128-135.
24. Yu, C., Chen, C. L., Gorycki, F. L., and Neiss, T. G. (2007) A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection. Rapid Commun. Mass Spectrom. 21, 497-502.
25. Lenz, E. M., Wilson, I. D., Wright, B., Partridge, E. A., Rodgers, C. T., Haycock, P. R., Lindon, J. C., and Nicholson, J. K. (2002) A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat. J. Pharm. Biomed. Anal. 28, 31-43.
26. Lenz, E. M., Lindon, J. C., Nicholson, J. K., Weeks, J. M., and Osborn, D. (2002) 19FNMR and directly coupled 19F/1H-HPLC-NMR spectroscopic investigations of the metabolism of the model ecotoxin 3-trifluoromethylaniline in the earthworm species Eisenia veneta. Xenobiotica 32, 535-546.
27. Ojanpera, S., Rasanen, I., Sistonen, J., Pelander, A., Vuori, E., and Ojanpera, I. (2007) Quantification of drugs in plasma without primary reference standards by liquid chromatography chemiluminescence nitrogen detection: application to tramadol metabolite ratios. Ther. Drug Monit. 29, 423-428.
28. Taylor, E. W., Jia, W., Bush, M., and Dollinger, G. D. (2002) Accelerating the drug optimization process: identification, structure elucidation, and quantification of in vivo metabolites using stable isotopes with LC/MS" and the chemiluminescent nitrogen detector. Anal. Chem. 74, 3232-3238.
29. Corens, D., Carpentier, M., Schroven, M., and Meerpoel, L. (2004) Liquid chromatography-mass spectrometry with chemiluminescent nitrogen detection for on-line quantitative analysis of compound collections: advantages and limitations. J. Chromatogr., A 1056, 67-75.
30. Gammelgaard, B., Hansen, H. R., Sturup, S., and Moller, C. (2008) The use of inductively coupled plasma mass spectrometry as a detector in drug metabolism studies. Expert Opin. Drug Metab. Toxicol. 4, 1187-1207.
31. Cuyckens, F., Balcaen, L. I. L., Wolf, K., Samber, B., Van Looveren, C., Hurkmans, R., and Vanhaecke, F. (2008) Use of the bromine isotope ratio in HPLC-ICP-MS and HPLC-ESI-MS analysis of a new drug in development. Anal. Bioanal. Chem. 390, 1717-1729.
32. Lappin, G., and Stevens, L. (2008) Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 4, 1021-1033.
33. Tuniz, C., and Norton, G. (2008) Accelerator mass spectrometry: new trends and applications. Nucl. Instrum. Methods Phys. Res., Sect. B 266, 1837-1845.
34. Skipper, P., Hughey, B., Liberman, R., Choi, M., Wishnok, J., Klinkowstein, R., Shefer, R., and Tannenbaum, S. (2008) Bringing AMS into the bioanalytical chemistry lab. Nucl. Instrum. Methods Phys. Res., Sect. B 223-224, 740-744.
35. Chen, J., and Hsieh, Y. (2005) Stabilizing drug molecules in biological samples. Ther. Drug Monit. 27, 617-624.
36. Dell, D. (2004) Labile metabolites. Chromatogr. Suppl. 59, S139-S148.
37. Boelsterli, U. A. (2002) Xenobiotic acyl glucuronides and acyl CoA thioesters as proteinreactivc metabolites with the potential to cause idiosyncratic drug reactions. Curr. Drug Metab. 3, 439-450.
38. Glatt, H. (2000) Sulfotransferases in the bioactivation of xenobiotics. Chem.-Biol. Interact. 129, 141-170.
39. Watkins, P. B., Kaplowitz, N., Slattery, J. T., Colonese, C. R., Colucci, S. V., Stewart, P. W., and Harris, S. C. (2006) Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 296, 87-93.
40. Dennehy, M. K., Richards, K. A., Wernke, G. R., Shyr, Y., and Liebler, D. C. (2006) Cytosolic and nuclear protein targets of thiol-reactive electrophiles. Chem. Res. Toxicol. 19, 20-29.
41. Koen, Y. M., Gogichaeva, N. V., Alterman, M. A., and Hanzlik, R. P. (2007) A proteomic analysis of bromobenzene reactive metabolite targets in rat liver cytosol in vivo. Chem. Res. Toxicol. 20, 511-519.
42. Liu, J., Li, Q., Yang, X., van Breemen, R. B., Bolton, J. L., and Thatcher, G. R. (2005) Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study. Chem. Res. Toxicol. 18, 1485-1496.
43. Shin, N. Y., Liu, Q., Stamer, S. L., and Liebler, D. C. (2007) Protein targets of reactive electrophiles in human liver microsomes. Chem, Res. Toxicol. 20, 859-867.
44. Guengerich, F. P., and MacDonald, J. S. (2007) Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 20, 344-369.
45. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
46. Evans, D. C., and Baillie, T. A. (2005) Minimizing the potential for metabolic activation as an integral part of drug design. Curr. Opin. Drug Discovery Dev. 8, 44-50.
47. Kalgutkar, A. S., Gardner, I., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D. K., Lee, J. S., Nakai, Y., O'Donnell, J. P., Boer, J., and Harriman, S. P. (2005) A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6, 161-225.
48. Mannens, G. S., Hendrickx, J., Janssen, C. G., Chien, S., Van Hoof, B., Verhaeghe, T., Kao, M., Kelley, M. F., Goris, I., Bockx, M., Verreet, B., Bialer, M., and Meuldermans, W. (2007) The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans. Drug Metab. Dispos. 35, 554-565.